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One cannot discuss anti-dsDNA antibodies and lupus nephritis without discussing
the nature of Systemic lupus erythematosus (SLE). SLE is insistently described as a
prototype autoimmune syndrome, with anti-dsDNA antibodies as a central biomarker
and a pathogenic factor. The two entities, “SLE” and “The Anti-dsDNA Antibody,”
have been linked in previous and contemporary studies although serious criticism to
this mutual linkage have been raised: Anti-dsDNA antibodies were first described in
bacterial infections and not in SLE; later in SLE, viral and parasitic infections and in
malignancies. An increasing number of studies on classification criteria for SLE have been
published in the aftermath of the canonical 1982 American College of Rheumatology
SLE classification sets of criteria. Considering these studies, it is surprising to observe a
nearby complete absence of fundamental critical/theoretical discussions aimed to explain
how and why the classification criteria are linked in context of etiology, pathogenicity, or
biology. This study is an attempt to prioritize critical comments on the contemporary
definition and classification of SLE and of anti-dsDNA antibodies in context of lupus
nephritis. Epidemiology, etiology, pathogenesis, and measures of therapy efficacy are
implemented as problems in the present discussion. In order to understand whether
or not disparate clinical SLE phenotypes are useful to determine its basic biological
processes accounting for the syndrome is problematic. A central problem is discussed on
whether the clinical role of anti-dsDNA antibodies from principal reasons can be accepted
as a biomarker for SLE without clarifying what we define as an anti-dsDNA antibody, and
in which biologic contexts the antibodies appear. In sum, this study is an attempt to bring
to the forum critical comments on the contemporary definition and classification of SLE,
lupus nephritis and anti-dsDNA antibodies. Four concise hypotheses are suggested for
future science at the end of this analytical study.
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INTRODUCTION
SLE, lupus nephritis and anti-dsDNA antibodies represent
cores of this, in principal eclectic study. The narrative is
in its nature a critical view on definition of lupus nephritis
as part of the syndrome SLE, and its classification, etiology
and pathogenesis. In particular, the interrelationship between
numerous classification criteria has not been given priority
in the literature, notably not in the original manuscripts
presenting the 1982 American College of Rheumatology [ACR
(1)] and the 2012 Systemic Lupus Erythematosus International
Collaborating Clinics [SLICC (2)] sets of classification criteria.
In the introduction to the revised SLICC SLE classification
criteria it is stated “To ensure that there is a consistent
definition of SLE for the purposes of research and surveillance,
classification criteria for SLE are needed” (2). This statement
indicates that the ACR or SLICC classification criteria are
valid as reliable approaches to define SLE, even though
they do not define SLE as a homogenous disease since
the classification criteria by definition provides hundreds of
clinical phenotypes [discussed in (3)]. Figure 1 principally
demonstrates the clinical phenotype variability problem. One
basic problem is that the SLE study objects—the patients—
are included based on selected heterogeneous clusters of
classification criteria as defined in the 1982 ACR (1), the
1997 revised ACR (4), the 2012 SLICC criteria (2) and
recently the 2019 EULAR/ACR classification criteria for SLE
(5) instead of selecting cohorts of patients with a homogenous
phenotype like lupus nephritis and anti-dsDNA antibodies as
selection parameters.
This critical argumentation is not equally relevant to studies
on elements of systemic autoimmunity, like autoimmunity to
dsDNA in SLE [see e.g., (3, 6–16)]. Such studies are focused
on distinct autoimmune processes that are unlinked from a
solitary SLE context, as is indicated by the triangular1 link
of anti-dsDNA antibodies to SLE, infections and malignancies
(Figure 2A). Autoimmunity to chromatin structures is, however,
relevant for SLE (11, 13, 14, 35–38), and for pathogenesis of
organ manifestations like lupus nephritis, dermatitis and cerebral
affections, as discussed below.
Paradoxically, we are not able to explain why the classification
criteria by any combinations define SLE. The criteria are neither
etiologically nor pathogenetically linked to each other, a problem
that has not been seriously discussed [see published discussions
in (1, 2, 5)]. In the context, lupus nephritis may robustly stand on
own feet as a unique and identifiable disease, as unintentionally
(?) indicated in the SLICC criteria, as this set of criteria
says that a person may have SLE if positive for anti-dsDNA
antibodies and demonstrating proteinuria. Thus, we are not able
to provide a concise definition of SLE and lupus nephritis, but
we identify SLE when we encounter patients. This is based on
inconsistent rather than coherent classification criteria, intuition,
and on experience.




SLE is an enigmatic disease, in which little of its pathogenesis
and less of its etiology is understood. In the history of SLE,
it is not possible to recognize penetrating studies that focus
on an autoimmune origin (in sense of etiology) of SLE, but
autoimmunity is recognized as a disease-modifying factor (in
sense of pathogenesis) that promote disease progression (3,
39–41). Rather, genetics in humans (42–44) and in mice (45,
46), infections (13, 15, 47–53), or cancers (13, 54–57) may be
relevant research foci to study molecular processes accounting
for etiology. The transformation of etiology into pathogenic
autoimmune processes are regarded central to understand the
imaginative syndrome SLE.
SLE: Syndrome, Etiology, and
Pathogenicity—Clarifying the Terms
(Lexical and Logic Semantics and
Simplifications)
Three terms are used to describe SLE: Syndrome, etiology,
pathogenesis. The term syndrome means concurrence—
symptoms appearing simultaneously. Etiology comes from
etymologistic: the study of causation, origination from the Greek
α
,
ιτιoλιγíα, aitiología, “giving a reason for” (α
,
ιτíα, aitía, “cause”;
and -λoγíα, -logía) (58). Etiology means the predisposition
of a disease or syndrome, and therefore something that
promotes pathophysiologic processes. Pathophysiology means
the origination and development of a clinical disease. If etiology
means the basic initiator, pathogenesis means the effector
of the disease. These terms are important to consider if we
aim to understand how to categorize hypotheses, basic and
clinical science on SLE—and how to probe hypotheses aimed
to understand the impact of classification criteria. There exists
no evidence that SLE is promoted by an autoimmune etiology,
because the 11 ACR or 17 SLICC criteria are definitively
not connected to a common etiology. The criteria may per
statements appear cumulatively in the body at different time
points as specified (1, 2) and interpreted in the study of Arbuckle
et al. (59). Considering the highly diverse nature of individual
classification criteria, the criteria may in fact rely on different
etiologies, and consequently on different pathogenic processes.
The autoimmune pathogenesis involved in evolution of the
syndrome SLE may therefore be set in motion not by a uniform
underlying etiology, but by etiologies promoting individual
classification criteria. A definition of SLE as a syndrome
(3, 12, 39, 60) is therefore etymologically and theoretically
unjustified. There are few discussions related to this problem,
but are tangentially approached by Touma et al. (61).
Furthermore, accepting that criteria like “The anti-dsDNA
antibody” may appear timely unlinked from a clinically
overt pathogenic process challenges the Witebsky postulates
attempting to define a disorder as autoimmune and pertained by
a specific autoimmune response (62, 63) in analogy to the Koch’s
postulates to define a causative relationship between a defined
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FIGURE 1 | Principal problems linked to classification of systemic lupus erythematosus (SLE). Classification of SLE patients according to The American College of
Rheumatology (ACR) (A1,A2) or by The Systemic Lupus International Collaborating Clinics Criteria (SLICC) (B1,B2) classification criteria are descriptively
problematized. Each of the classification systems identify a substantial diversity of clinical phenotypes. The 11 ACR criteria is presented by numbers (A1, the
classification criteria are presented as a focused table in A2). Five patients are demonstrated. The patients share some criteria, but diverge with respect to others, and
their clinical phenotypes differ individually. Similarly, each of 11 clinical and 6 immunological SLICC criteria are presented by numbers (B1, the classification criteria are
presented as a focused table in B2). These chaotic figures (A1, B1) demonstrate that the use of the ACR and the SLICC criteria is problematic as bases for scientific
analyses covering genetics, etiology, pathogenesis, and response to experimental therapy in patient cohorts as the study objects do not represent a homogenous
group of patients. The patients in these figures are fictive but they reflect problems with the ACR and SLICC criteria in real life (Part of this figure (A) is a reprint with
permission of Figure 1 in Rekvig (3).
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FIGURE 2 | Principal problems linked to the ACR and SLICC classification criterion “The anti-dsDNA antibody” (criterion 11 in ACR) or “Anti-dsDNA” (criterion 6,
Immunological criteria, SLICC). Principal simplified problems are linked to the inadequate terminology of the anti-dsDNA antibodies. One problem [demonstrated in
(A)] illustrates that “The anti-dsDNA antibody” is not unique for SLE, but appears regularly in context of infections and malignancies (see text for details). Little is
examined whether anti-dsDNA antibodies are pathogenic and cross-reactive in the latter two categories of conditions (question marks in A) as they are in SLE. This
triangular nature of anti-dsDNA antibodies has not been considered in the classification criteria, and poorly in the relevant literature on SLE. The second dominant
problem considered for the “Anti-dsDNA antibody” is that the antibodies are presented as if “it” is monospecific for dsDNA. This has over decades crystallized the
conception that different assay systems detect antibodies possessing different avidities but not different specificities! This conflict is principally demonstrated in
(B). The “ssDNA/dsDNA” is categorized in 4 main categories with 5 subcategories for mammalian dsDNA, 2 for infectious dsDNA and 2 for cross-reaction of
anti-dsDNA for renal and non-renal proteins/phospholipids (see Table 1 for details on the latter category). Antibodies for all these dsDNA structures have been
identified by conventional assay systems, like ELISA in physiological salt (elongated/bent B dsDNA), in high salt (Z dsDNA), cruziform dsDNA, bacterial and viral
dsDNA in addition to heterogeneous binding to proteins and phospholipids. The idiom that anti-dsDNA antibodies bind dsDNA in a singular form as in the ACR or
SLICC classification systems must be challenged by the multifaceted recognition pattern of anti-dsDNA antibodies as informed in (B). Thus, data in this figure require
that assay systems for anti-dsDNA antibodies relates to categorized structural dsDNA specificities. Lack of implementation of the structural and molecular recognition
pattern recognized by individual anti-dsDNA antibodies undermine the potential clinical impact of anti-dsDNA antibody sub-specificities.
microbe and a consequently defined disease2. The essence
of the Witebsky postulates is that an autoantibody account
for a given tissue damage, and the characteristic pathological
changes can be reproduced upon transfer of the autoantibody
(or suspected T cells) into experimental animals. This is
discussed below.
2“Koch”. Random House Webster’s Unabridged Dictionary.
SLE: A Short History of Non-linear Periodic
Paradigm Shifts Leading to Our Times
Syndrome
The syndrome originally being described as a skin disease in
antiquity has evolved into a complex disease through milestones
defined as non-linear paradigm shifts (64–66).What can we learn
from this still ongoing evolution of SLE, and how can we include
the term SLE into a scientifically insinuated disease entity? In
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this context, the complexity of SLE and patients suffering from
SLE has been thoughtfully and eruditely presented by David
Isenberg (67).
The transformation of SLE from a serious monosymptomatic
skin disease into a syndrome has in Ludvik Fleck’s (68) and
Thomas Kuhn’s (69) sense not evolved linearly, but through
radical paradigm shifts. The central milestones appeared after
studies in the 1850ies and their aftermaths. Central perceptions
derive from paradigms settled by Cazenave in 1850ies (70),
and later by Kaposi (71), Osler (72, 73), and Jadassohn [(74),
reviewed in (64, 65, 70, 75)]. Through these paradigm shifts, the
definition of SLE has evolved into that of a syndrome including
systemic affection of viscera (71, 73) and later also comprising
immunological, biochemical and hematological parameters (1,
2, 5). This has resulted in new authoritarian descriptions of
SLE as in the canonical ACR (Figure 1A) or SLICC (Figure 1B)
sets of criteria. With still ongoing expansion of classification
criteria we have not reached a consensus on what SLE is, or
what its etiology or pathogenesis are. Thus, the paradigm shifts
resulting in the modern perception of SLE has not been very
helpful to understand what SLE basically is, but they provided an
understanding of its complex and systemic nature. An intriguing
question we can raise in this context is if SLE of today at all is the
disease known in antiquity as a skin disease.
When SLE should be interpreted from principals as those
observed, implemented and decoded in the classification criteria,
the positivists3 would (and indeed do so!) describe the syndrome
through collection of facts/criteria. The elements that exert this
collection of facts have, however, not reached a logic description
based on firm scientific data beyond statistical co-appearance
- cumulatively or simultaneously. By this, the syndrome SLE
can, as it is understood today, be classified by a hermeneutic4
approach to understand its nature.
SLE: A Primary or Secondary Autoimmune
Syndrome; Etiology vs. Pathogenesis
A classical statement promotes SLE as a prototype complex
autoimmune syndrome (1, 2, 5, 61, 76, 77). However, this
statement is standing in a certain contextual, but contrafactual
paradigm hampered by one central logical problem: We do not
understand an etiological origin of the classification criteria,
or what the link between the current criteria are. We have
till now not determined if they at all emerge from an inner
biological coherence. Theoretically, they might be determined
by a common etiology, or by diverse pathogenic processes
that account for the apparently non-coherent classification
criteria. If we aim our studies to understand the meaning of
all the classification criteria for SLE, we need to distinguish
the syndrom’s etiology from the (secondary) pathogenicity that
account for the manifold of the syndrome’s classification criteria.
3Positivism: A philosophical system founded by Auguste Comte, concerned with
positive facts and phenomena, and excluding speculation upon ultimate causes or
origins.
4Hermeneutics is the theory and methodology of interpretation, especially the
interpretation of biblical texts, wisdom literature, and philosophical texts.
The latter statement has not been profoundly discussed in
the literature. Only few exceptions from this offensive comment
on the classification criteria have been discussed. One obvious
exception is expressed in the SLICC criteria; a patient is said to
have SLE if having two criteria fulfilled: nephritis (proteinuria)
concurrently with anti-dsDNA antibodies (2). Here, the antibody
is strategically and logically linked to renal inflammation in a
causal relationship: The antibody as inducer of de facto renal
inflammation in accordance with the Witebsky proposals. The
other comes from a study published by Pisetsky et al. (77)
where they introduce a principal system for categorization of SLE
phenotypes; i.e., defining phenotypes of SLE in groups according
to interrelated criteria to define subgroups of SLE. In fact,
Pisetsky’s suggestion resembles data from Isenberg et al. where
they upon longitudinal studies of 988 SLE patients identified
different clusters of phenotypes (76). The newly suggested
revision of the criteria published by Aringer et al. (5) and Touma
et al. (61) do not help much here, as these revised criteria cement
non-interrelated affections into an enigmatic disease entity! This
is recently critically analyzed and discussed by Petri et al. (78).
SLE: A Cumulative Model for the
Classification of SLE Raises Problems
Linked to the Terms Etiology and
Pathogenesis
Relevant in the present context is to understand what ties
the evolving number of classification criteria together aimed
to classify the syndrome SLE—a common etiological or a
common pathogenetical mechanism? Or are they tied together
as a result of a domino effect of pathogenic events: one
leads to other events that are not initiated by the primary
etiology? And what is the rationale behind the statements in the
classification criteria that any events (processes, clinical criteria,
deviating laboratory parameters) counts over the timeline of the
syndrome. Classification criteria that appear disparate in time
count cumulatively. According to the definition of the term
syndrome—concurrence—this term does not harmonize with the
statement that the criteria may appear simultaneously or at any
time point in the history of a patient. If the criteria are related
to each other as inducers (autoimmunity?) or responders (organ
affections?) then how can the one or the other appear disparate
over years? This is an accepted, although contrafactual, statement
in the classification criteria which is not in agreement with the
Witebsky postulates to define a disease as caused by a specific
autoimmune antibody or an autoimmune T cell.
On the other hand, an autoimmune pathogenesis of SLE may
be a valid term for some of the criteria (like lupus nephritis or
lupus-related skin and cerebral affections) characterizing SLE.
In harmony with this, data demonstrate that the kidney disease
evolves and is maintained (pathogenesis), but not proven to be
initiated (etiology) by autoimmune responses with anti-dsDNA
antibodies as the central pathogenic factor (11, 16, 33, 79–81).
However, other criteria than lupus nephritis, lupus dermatitis
(82), and certain cerebral affections (83), have pathogenic origins
that are beyond the impact of anti-dsDNA antibodies. It may
be wise to probe the term autoimmune pathogenesis with the
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Witebsky postulates (62, 63) to establish a causative relationship
between a specific autoimmune response and a subsequent
autoimmune disease.
Another principal problem related to the use of classification
criteria is based on epidemiological studies and studies on the
effect of experimental therapeutic modalities. A critical question
must therefore be if patients implemented in multicenter-based
ACR or SLICC defined cohorts are homogenous to a degree that
allow us to validate results related to basic aspects of SLE, like its
etiology, pathogenesis, epidemiology and effect of experimental
therapy. This somewhat pedantic discussion is important since
SLE is regarded as an integrated and unified syndrome—however
without parameters that justify this assumption.
CURRENT APPROACHES TO STUDY THE
NATURE OF SLE
The contemporary ACR or SLICC criteria-related definitions
of SLE and its canonical link to autoantibodies against dsDNA
(10, 13, 14) can be confronted by argumentations at different
theoretical levels;
i. Do we have clear evidence-based definitions of the syndrome
and its marker antibodies;
Our contemporary insight into the syndrome SLE derives from
three mainstream types of scientific approaches. One is based
on identifying basic hypotheses related to separate processes
accounting for individual classification criteria. The second
approach is aimed to analyse why a wide diversity of clinical,
biological, and biochemical parameters in SLE cohorts are
implemented as diagnostic and classification measures. The
third is a neglected approach; lack of studies to elucidate why
the diverse classification criteria are appearing clustered in
SLE. These approaches have not guided us into evidence-based
definitions of SLE and its canonical marker antibodies. If we are
going further into these problems, we do not need to generate
more classification criteria, we need to select conservative and
uniform selection criteria in order to implement homogenous
patient cohorts, like those positive for proteinuria and anti-
dsDNA antibodies. By this, we can analyse whether these two
selection criteria define SLE and classification criteria that are
pathogenetically linked to nephritis and anti-dsDNA antibodies.
To select cohorts based on all combinations of classification
criteria, as demonstrated in Figure 1, may yield some statistically
significant combination of symptoms/parameters, but not
information on pathogenesis and even less on etiology of each
criterium or SLE itself.
ii. Do we perform sound theoretical considerations applied to
etiology and to pathogenesis of the syndrome itself as opposed
to its individual criteria;
Such requested studies are difficult to identify in historical
or contemporary studies. One possible approach could be to
identify analytically or through studies of relevant literature
etiological and pathogenetic processes accounting for individual
classification criteria.
iii. Can we implement open-minded reservations in this
argumentation, or is this approach dominated by
dogmatic conclusions deriving from statistical data (the
positivistic approach)?
In my opinion we have to generate clear reservations when
implementing newly and previously defined classification
criteria. If statistically significant associations of criteria should
be weighted, then biological and pathogenical studies must be
performed to promote information as to why these criteria tell
us something about SLE.
Therefore, prevailing limitations of contemporary cohort
studies are founded on analyses of highly heterogenic groups of
SLE patients [discussed in (3)]. This simple fact makes studies of
SLE difficult without clearly defined and reflected hypotheses (see
suggested hypotheses in the conclusion section).
WHAT MAY EMERGE FROM THESE
THEORETICAL TRIBULATIONS AND
CONSIDERATIONS?
A conclusion of these reflections and concerns is that we
need to reconsider how we classify SLE. We also need to
generate new testable hypotheses, and accordingly to perform
studies on clinically homogenous patient cohorts, and to define
biomarkers relevant for such homogenous cohorts of SLE
patients. Basically, we need to determine whether revised or
contemporary classification criteria for SLE are etiologically or
pathogenetically logic and understandable. In sum, we must
prioritize, or categorize according to Pisetsky’s definition (77), the
criteria to approach a more uniform and homogenous definition
of the syndrome SLE. For example, a homogenous cohort could
be patients demonstrating anti-dsDNA antibodies concurrently
with proteinuria, taking only these two criteria into account. In
that context it would be intriguing to observe which of clinical or
laboratory parameters would deviate from normal values.
“THE ANTI-DSDNA ANTIBODY” - AN
ACCOUNT TO ITS NATURE AND
STRUCTURAL DNA SPECIFICITIES
This heading indicates a problem. “The anti-DNA antibody,”
as defined in ACR or SLICC classification criteria, is just that,
and does not reflect anti-dsDNA antibodies specific for various
dsDNA structures (see Figure 2B). This statement underscores
the problems defined in the following proclamations. Anti-
dsDNA antibodies occur in SLE, are a classification criterion for
SLE, exist in autoimmune syndromes other than SLE (13), in
bacterial (48, 53, 84), viral (49, 85–87), and parasitic infections
(88), and in cancers [(89), see Figure 2A). Importantly, these sets
of anti-dsDNA antibodies have multiple specificities for unique
DNA structures (Figure 2B). They have a pathogenic impact in
SLE (but not in infections or in cancers?), and they may even
be detected in healthy individuals [see general discussions in
(10, 13, 14)].
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Anti-dsDNA Antibodies: Appearing in
Principally Different Clinical Conditions
The annexation of “The anti-DNA antibody” as a criterion for
SLE does not communicate its pertinent clinical impact aside
from simply being claimed to be involved in lupus pathogenesis
[although how is still disputed (11)] or in which circumstances
the antibodies are clinical epiphenomena distinctively separated
from their assumedly pathogenic effects or their status as
biomarker. See in this context a concise discussion of the
term biomarker by Califf (90). Thus, rather of being a unique
biomarker antibody for SLE, the antibodies demonstrate clinical
associations with SLE, infections and malignancies, aside from
appearing sporadic in other disorders (13).
In SLE, anti-dsDNA antibodies are pathogenic in context of
lupus nephritis (11, 79), dermatitis (82, 91), and in certain forms
of cerebral lupus (27, 83, 92).Whether these pathogenic pathways
are determined by cross-reaction with non-DNA structures
(see Table 1 for examples) or by homologous recognition of
chromatin/dsDNA exposed in e.g., glomeruli (11, 93, 94), skin
basement membranes (82), or in the brain (27) is still not firmly
established. These clinical origins of anti-dsDNA antibodies has
not been seriously considered in the classification criteria, nor
in the relevant literature on anti-dsDNA antibodies and SLE
[discussed in (1, 2, 5, 13, 14, 39)].
Anti-dsDNA Antibodies: Recognition of
Disparate Unique dsDNA Structures and
Not Simply dsDNA (a Review of Relevant
Literature)
In the modern history of DNA discoveries, different forms of
DNA structures have been described in highly focused research
projects directed at describing what DNA is, which DNA
structures exist, and their role in facilitating and regulating
transcription of genes. Therefore, the second principal problem
to be considered is that the antibodies are presented as if
they constitute one specificity for dsDNA— “The anti-dsDNA
antibody” (1, 2, 5). “The anti-dsDNA antibody” is not an
unambiguous term, and the antibody reflects specificities to
a variety of structures far beyond the canonical double helix
structure. These structures represent the contexts in which
dsDNA is presented to the immune system. The term “The anti-
dsDNA antibody” comprises specificities toward ssDNA (95),
Z DNA [left-handed dsDNA (96–99)], bent and elongated B
DNA [right-handed dsDNA (100, 101)], diverse ss- and ds-
RNA sequences and RNA-DNA double-strand hybrids (102,
103), folded and unfolded cruciform DNA structures (104,
105), bacterial DNA (106, 107), and finally different forms of
viral dsDNA (108–110) that differ from mammalian dsDNA
structurally and serologically (85, 110). Among these individual
DNA structures, the most enigmatic in an auto-immunogenic
context is the mammalian B form of dsDNA, since many
of the other DNA structures were proven immunogenic, but
this was not the case with mammalian B DNA. Therefore,
over decades B DNA was considered non-immunogenic [(99,
111, 112), reviewed in (13)]. Anti-dsDNA antibodies further
cross-react with a large panel of proteins and phospholipids.
TABLE 1 | Examples of anti-dsDNA antibodies that cross-react with non-DNA
structures.




Several cross-reactive activities presented at “Fifth
International Workshop on anti-DNA anti-bodies in London
2002 to highlight relevant
properties of pathogenic anti-DNA antibodies” (22)
Phospholipids (23)
Nucleosomes (24)
Platelet integrin GPIIIa 49–66 (25)
TLR 4 (26)
NR2 glutamate receptor (27)
Cell surface proteins*** (28)






*Mono-specific anti-Entactin antibody is included to suggest a control non-cross-reactive
antibody to determine if dsDNA as a cross-reactive specificity is required to gain
pathogenic potential.
This heterogenous group of antigens targeted by anti-dsDNA
antibodies are exemplified in Figure 2B andTable 1. The referred
antibody specificities have been detected in natural situations
(13), while antibodies have at least been raised experimentally to
cruciform DNA structures (105).
One relevant question in this regard is whether fine molecular
DNA antibody-specificities differ between their appearance in
infections, malignancies and in SLE, as some antibodies may
appear depending on the clinical situation, as is demonstrated
for experimental induction of Z dsDNA but not B dsDNA
specific antibodies in mice (99) although both appear in SLE.
A similar observation relates to the fact that the frequency of
antibodies to elongated mammalian dsDNA, as nucleosomal
linker dsDNA, is higher than antibodies to bent dsDNA as in
the core mononucleosome, both present on the same chromatin
structure (101, 113, 114) or to bent dsDNA as in the plasmid of
Crithidia luciliae (100).
ANTI-dsDNA ANTIBODIES: ASSAY
CONDITIONS DO NOT PER SE
DETERMINE LEVELS OF ANTIBODY
AVIDITIES, BUT REFLECT DISPARATE
UNIQUE dsDNA SPECIFICITIES
The term “The anti-dsDNA antibody” has over decades shaped
the concept that different assay systems detect antibodies
possessing different avidities to dsDNA, but not different
molecular or structural dsDNA specificities. This problem has
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not been considered when discussing binding of antibodies to
dsDNA in principally different antibody assay systems. This
conflict is demonstrated in Figure 2B. Antibodies binding the
“ssDNA/dsDNA” structures are in the figure classified into 4
main categories with 5 subcategories for mammalian dsDNA, 2
for infectious dsDNA and 2 for cross-reaction of anti-dsDNA
antibodies with renal and non-renal proteins and phospholipids
(Figure 2B, see Table 1 for details on the latter categories). These
categories and subcategories are examples of pertinent diversity
of dsDNA structures recognized by this family of antibodies
[see e.g., (115–117), all specific for functional DNA structures or
infectious-derived chromatin/DNA].
Antibodies for these dsDNA structures have been identified
by conventional assay systems, like ELISA-based detection of
anti-dsDNA antibodies against dsDNA in physiological salt; in
high salt (Z dsDNA); cruziform dsDNA; bacterial and viral
dsDNA [summarized in (10, 13)]. The idiom that anti-dsDNA
antibodies are presented in a singular form (“The dsDNA”)
must be challenged by the comprehensive structural recognition
diversity. This clearly opens for individual specificities generated
by different functional/structural states of dsDNA rather than
individual avidities (either low or high) linked to different assay
conditions. For example, if an antibody binds dsDNA in 2M
NaCl, it binds to a structure shaped in 2M NaCl; the Z dsDNA
(99, 118–121), and not because it has a high avidity over-winning
the strength of the high salt concentration as in the Farr assay
(122–124). This is also relevant for binding of other proteins
to dsDNA structures in various salt concentrations (125–127).
This difference is also evident from the fact that it is easier to
experimentally induce antibodies to Z dsDNA than to B dsDNA
(99). Similarly, antibodies that bind elongated dsDNA as in
ELISA and antibodies that bind bent dsDNA as in Crithidia
luciliae or in the core nucleosome may possess the same level
of avidities, but the antibodies recognize different structures,
elongated vs. bent dsDNA (128).
Thus, interpretation of data in Figure 2B demonstrate that
assay systems for anti-dsDNA antibodies detect specificities that
may have no or high potential impact as biomarker for SLE.
Their individual impact as classification criteria for SLE has,
however, not been investigated. This problem needs to be solved





The third principal problem considered for the anti-dsDNA
antibodies relates to its biological origin—what imposes
production of these antibodies. Normally, mammalian dsDNA
is non-immunogenic (111, 129, 130). Tolerance in a normal
homeostatic situation is maintained at several biological check-
point levels. B cells specific for dsDNA above a certain level
of affinity are deleted in the bone marrow (131, 132); their
antigen receptors are edited, with loss of affinity for dsDNA
[(133–135), see a general discussion in (136)]; or they may
appear anergic and non-functional (137, 138). Tolerance is also
controlled by T helper cells. CD 4+ T cell deletion prevents
autoimmunity, and CD 4+ T cells targeting chromatin-derived
peptides are normally anergic (139). This is evident from
experiments demonstrating that anergic CD 4+ T cells can be
rendered functional in response to IL-2 (140, 141), thus helping
B cells to transform into antibody-producing plasma cells. If
such cells are deleted (142, 143), this will prevent B cells to
receive competent CD4+ T cell signals to be transformed into
antibody-producing plasma cells. This situation is presented in
a simplified version in Figure 3A, where tolerant (anergic or
deleted) T cells are indicated.
In SLE, however, autologous chromatin may gain
immunogenic power because e.g., histone-specific CD 4+
T cell tolerance is truly terminated [Figure 3B, as described
in (144–146, 148, 149)]. Termination of histone-specific
CD4+ T cell tolerance is also easily achieved in experimental
contexts (140, 141, 150), thus demonstrating that CD4+ T cell
autoimmunity to chromatin-derived peptides is a latent property
of the normal immune system (141).
Data have been demonstrated that infections may provide
chromatin-binding proteins allowing cognate interaction of
chromatin-specific B cells and non-tolerant helper T cell specific
for the infectious chromatin-associated proteins [Figure 3C, see
e.g., (13, 15, 49, 50, 86, 147)]. This model is denoted the hapten-
carrier model for in vivo-induction of anti-chromatin/anti-
dsDNA antibodies.
Anti-dsDNA antibodies can also be produced through a
mechanism known as molecular mimicry (151–154), and the
central and important study by Lafer et al. published in 1981
opened this topic for further studies of molecular mimicry
as a potential driving force for appearance of anti-dsDNA
antibodies (23).
Which of these models (described in Figures 3B,C) are
operational in malignancies have not been investigated in
depth. Since malignancies are complicated by viral and bacterial
infections (155–157), this apprehension may hypothetically
authorize the hapten-carrier model for infection-induced anti-
dsDNA antibodies also in malignant diseases [as indicated in
Figure 3C, exemplified by the role of e.g., the viral dsDNA-
binding polyomavirus T antigen (50, 147)]. It is therefore
tempting to assume that infections in malignant diseases
may encompass a model in analogy to the one presented
in Figure 3C—the hapten-carrier model, as explained in the
next section.
Anti-dsDNA Antibodies: In vivo Expression
of Virus-Derived, DNA-Binding Proteins
Render Chromatin Immunogenic—
Evidence for the Hapten-Carrier Model
In Table 2, data are presented providing evidences that in vivo
expression of single dsDNA/chromatin-binding viral proteins
instigate the production of anti-dsDNA, anti-histone, and anti-
transcription factor antibodies like anti-TATA-binding protein
(TBP), anti-cAMP-response element binding protein (CREB)
antibodies in accordance with the hapten (dsDNA) -carrier
(viral dsDNA-binding protein) model. Molecular mimicry is less
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FIGURE 3 | Principal basic problems attempting to describe how or why
chromatin/dsDNA execute their immunogenic potential in vivo. Concerning the
origin of anti-dsDNA antibodies, they are not induced on a normal immune
background by exposure of pure autologous chromatin [A,
(7, 111, 112, 129, 134, 136)], although autologous chromatin may gain
immunogenic power in situations where helper T cell tolerance is truly
terminated as demonstrated in SLE [B, (141, 144–146)]. Infections may
provide chromatin-binding non-self-proteins that allow cognate interaction of
(Continued)
FIGURE 3 | chromatin/dsDNA-specific B cells and non-tolerant helper T cells
specific for the infectious chromatin-associated protein [C, see Table 2 for
examples (15, 49, 50, 86, 147)]. However, the possible immunogenicity of
chromatin in malignancies has not been explored in depth, although infections
as are predisposed for in cancers may encompass a model that is analogs to
the one presented in (C) (C is reprinted with permission from Figure 5 in
Rekvig (3)].
probable as explanation for production of anti-dsDNA in context
of these experiments, since in vivo-expression of a mutated
SV40T antigen, the SLT155T>S, rendered the SV40T antigen
non-dsDNA-binding and did not elicit production of anti-
dsDNA or anti-histone antibodies [Table 2, (147)]. Expression of
this mutant protein resulted, however, in antibodies to T antigen
(Table 2). Summarizing the models described in Figures 3A–C
and Table 2, tolerance is maintained in a normal individual,
terminated in SLE patients and lupus-prone mice, and tolerance
is also terminated in context of certain (complicating) infections.
Anti-dsDNA Antibodies: Tolerance to
Chromatin and the Role of Autologous
Chromatin-HMGB1 Complex and of DNase
1L3 Gene Deficiency in Promoting
Anti-dsDNA Antibody Responses
There is still, aside from generation of hypotheses (158–161),
no consensus as to whether pure autologous chromatin is
rendered immunogenic in context of reduced clearance of
apoptotic chromatin from dead and dying cells. Furthermore,
no firm evidence has been provided that exposure of neutrophil
extracellular traps (NETs) induce antibodies to dsDNA [see e.g.,
an insightful and still relevant discussion by Pieterse and van
der Vlag (162)]. These hypotheses have been discussed over
the last 2 decades, although sound experimental biologically
relevant evidences are still lacking [see a discussion in
(3, 13, 161, 162)].
Two independent observations may, however support the
view that autologous chromatin possesses auto-immunogenic
potential. Urbonaviciute et al. demonstrated that anti-
dsDNA/chromatin antibodies are induced upon exposure
of the high mobility group box protein 1 (HMGB1) tightly
attached to chromatin in apoptotic cells (150). In another study,
a null mutation in the DNase1L3 gene was described in SLE
patients with lupus nephritis (163). This deficiency correlated
with production of anti-dsDNA antibodies and lupus nephritis.
In agreement with the observational study in familiar SLE,
mice with experimentally deficient expression of the DNase 1L3
gene developed analogous anti-dsDNA antibodies and lupus
nephritis (164). Thus, in DNase 1L3 gene deficient individuals
extracellular degradation of chromatin is reduced and this
deficiency correlates with promotion of anti-dsDNA antibodies.
Thus, clearance deficiency of chromatin due to DNase 1L3
deficiency or release of extracellular chromatin in complex
with HMBG1 from apoptotic cells, are two potential sources of
complex autologous immunogens in both mice and humans.
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pRSV-BKT RSV LTRt Pyv T ag 681 ± 40 *** 715 ± 69 557 ± 112 318 ± 99 402 ± 91 (50, 147)
pRcCMV-BLT HCMV ie-1 Pyv T ag 1282 ± 186 871 ± 53 763 ± 87 468 ± 254 552 ±186 (50, 147)
pBS-BLT None Not expressed Not detected Not detected Not detected Not detected Not detected (50, 147)
pRcCMV-SLT155 HCM ie-1 SV 40T ag 573 ± 34 360 ± 46 259 ± 52 Not tested Not tested (50, 147)
pRcCMV-SLT155T>S HCM-ie-1 SV 40T ag
Mutant
non-dsDNA binding
442 ± 44 29% ± 2, 5**** Not detected Not tested Not tested (50, 147)
pRA 17 SCM-ie 1 EBNA 1 (69.7 kDa) Not tested EBNA-1, dsDNA,
Sm
Not tested Not tested Not tested (49)
All reported experiments are performed in BALB/c mice.
*TATA-binding protein.
**cAMP-response element binding protein.
***The results are given as titers. These were determined by ELISA analyses of the induced serum antibodies aimed to quantify autoantibodies in mice injected by various T antigen
expressing/non-expressing plasmids. The titers were determined from 2-fold dilution curves starting from dilution 1/100. The titers were defined as the reciprocal value of the dilution
giving 50% of maximal binding to wells, as determined by individual reference sera (147).
****These sera gave only marginal binding values as their binding at 1/100 dilution gave only 29% of the binding of a reference serum included in these assays.
ANTI-dsDNA ANTIBODIES AND LUPUS
NEPHRITIS
In the next section new aspects and interpretive problems will
be discussed in attempts to understand the link between anti-
dsDNA antibodies, lupus nephritis and SLE. This is on one hand
easy to do when considering the enormous amount of studies
accepting this linkage, but on the other hand difficult if basic
scientific data are considered critically.
SLE and “The Anti-dsDNA Antibody”
—Clinical and Biological Contexts
Anti-dsDNA antibodies were first described in an infectious
context in 1938–1939 (165–167), while in an autoimmune
context in 1957 (168–171). Despite considerable scientific efforts
we have not reached consensus on four fundamental aspects
of anti-dsDNA antibodies in SLE. These aspects are comprised
by four dogmatic areas: Their (i). Origin, (ii). Structural DNA
specificities, (iii). Pathogenic impact, and iv.Assumed link to SLE
[see discussions above and in (3, 11, 13, 14, 172)].
Anti-dsDNA Antibodies—Specificity
Critically Determines Nephrogenicity and
May Also Affect Alveolitis and Dermatitis?
Consensus has been established that anti-dsDNA antibodies
promote lupus nephritis. How they do so are still controversial.
The schisms divide scientists into two main interpretive groups.
One assumes that the antibodies bind chromatin exposed in the
kidneys (11, 173–176). This model is presented in Figure 4A. The
other mainstream model implies that nephritogenic anti-dsDNA
antibodies cross-react with intrinsic glomerulus basement
membrane (GBM) constituents (illustrated in Figures 4B, 5).
Which of the many autoantibodies described in SLE (183)
involved in promotion of lupus nephritis remain, however,
elusive. The cross-reacting antibodies assumed to be implicated
in lupus nephritis recognize among many ligands laminin (19,
184, 185), α-actinin (17, 18, 186), C1q (21), and entactin [(30, 33),
Table 1].
There is, however, one central problem in these studies. Each
of them focuses on one cross-reactive pattern and conclude
that the actual cross-reaction correlates with lupus nephritis.
Surprisingly, no discussion is presented that require a mutual
multicenter study that compare the different cross-reactions in
one cohort of lupus nephritis patients. This approach is awaited
because nephritogenic-prone cross-reactions can be identified,
and those that do not correlate with nephritis can be separated
as unrelated epiphenomena. It would be important also to test
if mono-specific antibodies not recognizing dsDNA, like those
monospecific for e.g., laminin, or α-actinin, have the potential
to promote lupus-like nephritis, as is suggested for the mono-
specific anti-entactin antibody presented in Table 2.
To understand the basis for these problems, it is necessary
to understand the unique processes of the two dominating
models for lupus nephritis. In Figure 4A, the chromatin model
is presented. On top, a principal presentation of the architecture
of a glomerulus is illustrated and in Line 1 a principal transition
of the mesangial matrix into the GBM is indicated.
In a classical progression of lupus nephritis, as described
in (NZBxNZW)F1 mice (177, 178) chromatin-IgG complexes
deposit in the mesangial matrix and form the early mesangial
nephritis (Figure 4A, line 2). One consequence of this
limited inflammation is silencing of renal DNase 1, reduced
fragmentation of chromatin from dead cells, and subsequent
accumulation of large chromatin fragments in complex with
IgG in the GBM [line 3, (178, 179)]. This process forms the
basis for a systemic glomerular inflammation and progression
of lupus nephritis into end stage renal disease. Silencing of
DNase 1 expression in this situation is unique to the kidney and
does not occur in other organs (179). Notably, the mesangial
matrix and the GBM share constituents like laminins, collagens
and entactin. As chromatin-IgG complexes bind laminins and
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FIGURE 4 | Principal problems to be solved before the chromatin or the cross-reactive model for lupus nephritis can be settled. In (A), the chromatin model is
presented. On top, a principal presentation of the architecture of a glomerulus is described. In line 1, the mesangial matrix (blue) and its transition into the GBM (red) is
principally demonstrated. In a classical progression of lupus nephritis (177, 178), chromatin-IgG complexes deposit in the mesangial matrix and form the early
mesangial nephritis (line 2). One consequence of this limited inflammation is silencing of the renal endonuclease DNase 1, a consequent reduced fragmentation of
chromatin from dead cells, and a subsequent deposition of large chromatin fragments in complex with IgG within the GBM [line 3, (178, 179)]. This forms the process
that promote glomerular inflammation and progression of lupus nephritis into end stage disease [discussed in (11)]. Silencing of DNase 1 expression in this situation is
unique to the kidney and does not occur in other organs (179). Since chromatin-IgG complexes bind laminins and collagens in the GBM with relatively high affinity
(180), and are released locally in the glomerulus, these observations may explain the canonical progression of lupus nephritis as described by Weening et al. (177).
This process may have therapeutic consequences, since chromatin prone to be deposited in GBM may be removed by flushing kidneys with the negatively charged
heparin or other analogous chaperone molecules [line 4, (181)5], and theoretically, the process may be interrupted upon upregulation of renal DNase 1 expression [line
5, (181)]. In (B), the glomerulus architecture is organized as in (A), and the matrix-GBM transition is principally illustrated (line 1). In the cross-reacting model,
cross-reacting anti-dsDNA antibodies bind intrinsic glomerular structures like entactin, laminin or collagen (line 2, see also data in Table 2). Since these antibodies
may bind ligands shared by mesangial matrix and GBM, the antibodies are expected to bind simultaneously in the mesangial matrix and in the GBM (line 2). Therefore,
the cross-reactive antibodies might well-initiate a glomerular inflammation more similar to the renal inflammation in Goodpasture syndrome (line 3) than to the stepwise
progression of lupus nephritis as illustrated in (A), lines 2 and 3. This consequence has not been considered in the relevant literature. One possible exception for this
Goodpasture-like inflammation would be an early production of antibodies specific for a ligand unique for the matrix (suggested in line 4) and that the mesangial
(Continued)
5Jenny Buckland. Therapeutic targeting of chromatin in lupus nephritis? Research Highlights Nat Rev Rheum. (2011) 7:132.
Frontiers in Immunology | www.frontiersin.org 11 October 2020 | Volume 11 | Article 569234
Rekvig Critical Viewpoints on SLE
FIGURE 4 | nephritis promoted by this particular antibody incites an inflammation that down-regulates renal DNase 1 and a subsequent exposure of undigested
chromatin fragments in complex with IgG anti-chromatin antibodies in GBM. This would promote the evolution of progressive lupus nephritis. In contrast to this
hypothetical model, lines 5 and 6 summarize progressive lupus nephritis according to the chromatin model. These principally conflicting models are summarized in
(A), lines 2 and 3 for the chromatin model, and in (B), line 2 for the cross-reactive model [This figure is a revised and extended version of Figure 4 in Rekvig et al. (182)
with permission from Elsevier (License number 4832930988362)].
FIGURE 5 | Principal problems linked to the cross-reactive model for lupus nephritis. The cross-reactive model inherits another provoking problem. Laminins, entactin
and collagens are obligate constituents in all basement membranes. This is relevant for basement membranes in glomeruli [see (11) for discussion], alveoli (187) and
skin (188). Accordingly, one should expect affection of glomeruli (A), alveoli (B) and skin (C) in analogy to Goodpasture syndrome [glomeruli and alveoli (189, 190)] and
autoimmune skin diseases (191–193). Surprisingly, in context of studies on the impact of cross-reactive anti-dsDNA antibodies as a model for pathogenesis of lupus
nephritis, the involvement in other organs has not been discussed or considered in the relevant studies. Observational and experimental studies argue against this
theoretical model. Analyses of nephritic glomeruli by electron microscopy (EM), immune EM (IEM), co-localization IEM, TUNEL co-localization IEM, allowed clear
indications that in vivo bound IgG were observed in electron dense structures (EDS) localized in the matrix and GBM [(194–196) summarized and discussed in (11)].
These EDS were TUNEL positive, and bound antibodies against histones, transcription factors and dsDNA added to sections in vitro. Because of the problematization
of how “The anti-dsDNA antibody” promotes lupus nephritis, questions that are illustrated in Figure 4, should be considered and focused on in future studies on the
distinct autoimmune pathogenesis of nephritis [A in this figure is a truncated reprint of Figure 4 in Rekvig et al. (182) with permission from Elsevier (License number
4832930988362)].
collagens with relatively high affinity (180), and are released
locally in the glomerulus, these observations may explain
the canonical progression of lupus nephritis from mesangial
nephritis into end-stage disease as described by Weening et al.
(177). This process may have specific therapeutic consequences,
since chromatin prone to be deposited in GBM may be removed
by flushing kidneys with heparin or other analogous chaperone
molecules [Figure 4A Line 4, (181)], and theoretically, the
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process will assumedly be interrupted upon upregulation of renal
expression of DNase 1 [(181), as indicated in Figure 4A, line 5].
Such experimental approaches are awaited.
In Figure 4B, the architecture of the glomerulus is
repeated, and the transition of the mesangial matrix into
the GBM is indicated (Figure 4B, line 1). Cross-reacting anti-
dsDNA antibodies bind non-dsDNA, intrinsic mesangial
matrix and GBM structures like entactin, laminin or
collagen (Figure 4B, line 2); thus, these antibodies may
from theoretical arguments simultaneously bind ligands
shared by the mesangial matrix and GBM. If this model is
correct, the cross-reactive antibodies might well initiate a
glomerular inflammation similar to the renal inflammation
in Goodpasture syndrome (Figure 4B, Line 3). The model
may indicate that mesangial nephritis does not precede
progressive lupus nephritis, but appear simultaneously. This
consequence of a cross-reaction has not been considered in
the literature.
One possible exception for this would be an early
production of antibodies specific for a ligand unique for
the matrix (suggested in Figure 4B, line 4) or that the
mesangial nephritis promoted by this particular antibody
incites an inflammation that down-regulates renal DNase
1 and subsequent exposure of large chromatin fragments
in GBM and thereby the evolution of progressive lupus
nephritis. In contrast to this hypothetical model, Figure 4B
lines 5 and 6 summarize progressive lupus nephritis
according to the chromatin model. These principally
conflicting models are summarized in Figure 4A, lines 2–
3 for the chromatin model, and Figure 4B, line 2 for the
cross-reacting model.
The cross-reactive model also inherits another provoking
problem that is not regarded in the literature. Since e.g.,
laminins, entactin, collagens, and other ligands are obligate
constituents in all basement membranes, this is relevant also
for basement membranes in glomeruli [discussed in (11)],
alveoli (187) and skin (188). Accordingly, one would expect
affection of glomeruli (Figure 5A), alveoli (Figure 5B) and
also skin (Figure 5C) in analogy to Goodpasture syndrome
[glomerulonephritis and alveolitis (189, 190)], and to
autoimmune skin diseases (191–193, 197). Surprisingly, in
context of studies on the impact of cross-reactive anti-dsDNA
antibodies as central in the pathogenesis of lupus nephritis,
the involvement in other organs has not been considered in
relevant studies.
Concluding Remarks and Four Concise
Hypotheses
SLE is a complex serious disease considered to rely on an
autoimmune pathogenesis. One central question arises from
the discussions above: Is SLE with nephritis another syndrome
than SLE without nephritis? And are the same clusters of
classification criteria, and the same sets of biomarkers linked
to SLE with and without nephritis or with or without anti-
dsDNA antibodies informing about the same fundamentals
of the disease? We do not need more classification criteria
in the aftermath of those tentatively identified till now. For
now, we first have to develop an understanding why they
appear in clusters and thereby why they define the syndrome
SLE. Today, these problems are hidden from our perspective
on SLE in our search for new classification systems for
SLE. We need a penetrating and better theoretical model
for SLE, to generate a basis for new and stringent cohort
studies. The discussions given above on classification systems
for SLE, anti-dsDNA antibodies and phenotypes of lupus
nephritis must be imperative to develop new concise and
testable hypotheses.
The following hypotheses may be considered.
• Analyzing cohorts of SLE patients selected by ACR or SLICC
criteria will identify a larger spectrum of deviating clinical and
biological parameters than homogenous cohorts of patients
selected based on e.g., proteinuria and anti-dsDNA antibodies.
• The “Anti-dsDNA antibody” has lower impact as a
classification criterium than anti-dsDNA antibodies specific
for certain unique dsDNA structures.
• Different assay systems detect antibodies with different
structural dsDNA specificities and not different avidities of the
antibodies detected in the individual assay systems, thus this
may result in different phenotypic presentations of SLE.
• If crossreacting anti-dsDNA antibodies bind renal basement
membrane structures like laminin, entactin and collagen, the
probability that they bind basement membranes in other
organs is high. If not, onemay question whether cross-reaction
is of clinical significance.
In sum, SLE remains an enigmatic disease despite (or because)
implementing new classification criteria; anti-dsDNA antibodies
in clinical medicine are still poorly defined; lupus nephritis
pathogenesis needs to be defined with respect to specificity of
nephritogenic anti-dsDNA antibodies: Specificity for dsDNA or
cross-reacting renal antigens.
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